Bioterrorism And Gene Editing: Can Crispr Tool Be Used As Biological Weapon In War?
By Himanshu Goenka,
IB Times
| 12. 14. 2016
Crispr is a tool that allows for genes to be edited, and has great potential in the treatment of a wide range of diseases, including some for which there is currently no known cure. It rose to prominence in 2015, when it was chosen as the breakthrough technology of the year by the American Association for the Advancement of Science, and became even better known in 2016 when scientists behind it were strong contenders for the Nobel Prize (which it finally didn’t win) and also appeared in Time magazine’s readers’ poll for the Person of the Year title.
Even as a legal battle is currently underway for the patent rights to Crispr (its Cas9 variant, to be specific), the technology is far from perfect right now — scientists are still working on making it more precise and the first human test involving a gene modified using Crispr took place only in October. And yet, it has made it to the list put together by U.S. intelligence agencies on national security threats.
However, in a somewhat surprising announcement in February 2016...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...